Document is current
Any future updates will be listed below
-
Authors
Karnik, Varun
Colombo, Sebastiano Maria
Rickards, Leah
Heinsar, Silver
See Hoe, Louise E.
Wildi, Karin
Passmore, Margaret R.
Bouquet, Mahe
Sato, Kei
Ainola, Carmen
Bartnikowski, Nicole
Wilson, Emily S.
Hyslop, Kieran
Skeggs, Kris
Obonyo, Nchafatso G.
McDonald, Charles
Livingstone, Samantha
Abbate, Gabriella
Haymet, Andrew
Jung, Jae-Seung
Sato, Noriko
James, Lynnette
Lloyd, Benjamin
White, Nicole
Palmieri, Chiara
Buckland, Mark
Suen, Jacky Y.
McGiffin, David C.
Fraser, John F.
Li Bassi, Gianluigi https://orcid.org/0000-0002-0816-0880
- License Information
-
More Information
Article History
Received: 12 May 2024
Accepted: 9 September 2024
First Online: 27 November 2024
Declarations
:
: The project was approved by Queensland University of Technology (QUT) Animal Ethics Committee (Approval #16-1109). Ratified by the University of Queensland AEC (QUT/393/17/QUT), experiments were performed in accordance with the National Health and Medical Research Council (NHMRC) Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (8th Edition 2013), the Animal Care and Protection Act 2001 (QLD) and complied with the ARRIVE Guidelines.
: Not applicable.
: Professor John Fraser is the CEO of the Quantum Medical Innovation Fund and De Motu Cordis Pty Limited. He is also the co-founder of BiVACOR™ Pty Ltd. In addition, Prof. Fraser and his research group collaborate with Australian Red Cross Lifeblood, Fisher and Paykel healthcare, Mallinckrodt Pharmaceuticals and CSL. Professor Fraser receives reimbursement for travel costs when presenting research created collaboration with Fisher and Paykel Healthcare. Professor David McGiffin provides consultancy services to Abbott. This has no direct impact on the contents of the manuscript. The other authors do not have any conflict of interest.
